C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter H—Medical DevicesPart 812—Investigational Device ExemptionsSubpart B—Application and Administrative Action

21 C.F.R. § 812.30 (2026)

FDA action on applications

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1997–2020 10citing cases
At a glance

Courts have cited this section in 10 opinions since 1997. The most litigated part is subsection (b)(4) (2 cases).

(a) Approval or disapproval. FDA will notify the sponsor in writing of the date it receives an application. FDA may approve an investigation as proposed, approve it with modifications, or disapprove it. An investigation may not begin until:

(1) Thirty days after FDA receives the application at the address in § 812.19 for the investigation of a device other than a banned device, unless FDA notifies the sponsor that the investigation may not begin; or

(2) FDA approves, by order, an IDE for the investigation.

(b) Grounds for disapproval or withdrawal. FDA may disapprove or withdraw approval of an application if FDA finds that:

(1) There has been a failure to comply with any requirement of this part or the act, any other applicable regulation or statute, or any condition of approval imposed by an IRB or FDA.

(2) The application or a report contains an untrue statement of a material fact, or omits material information required by this part.

(3) The sponsor fails to respond to a request for additional information within the time prescribed by FDA.

(4) There is reason to believe that the risks to the subjects are not outweighed by the anticipated benefits to the subjects and the importance of the knowledge to be gained, or informed consent is inadequate, or the investigation is scientifically unsound, or there is reason to believe that the device as used is ineffective.

(5) It is otherwise unreasonable to begin or to continue the investigation owing to the way in which the device is used or the inadequacy of:

(i) The report of prior investigations or the investigational plan;

(ii) The methods, facilities, and controls used for the manufacturing, processing, packaging, storage, and, where appropriate, installation of the device; or

(iii) Monitoring and review of the investigation.

(c) Notice of disapproval or withdrawal. If FDA disapproves an application or proposes to withdraw approval of an application, FDA will notify the sponsor in writing.

(1) A disapproval order will contain a complete statement of the reasons for disapproval and a statement that the sponsor has an opportunity to request a hearing under part 16.

(2) A notice of a proposed withdrawal of approval will contain a complete statement of the reasons for withdrawal and a statement that the sponsor has an opportunity to request a hearing under part 16. FDA will provide the opportunity for hearing before withdrawal of approval, unless FDA determines in the notice that continuation of testing under the exemption will result in an unreasonble risk to the public health and orders withdrawal of approval before any hearing.

[45 FR 3751, Jan. 18, 1980, as amended at 45 FR 58842, Sept. 5, 1980]
The 10 cases that cite 21 C.F.R. § 812.30 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENAda M. Martin v. Telectronics Pacing Sys., Inc., 105 F.3d 1090 (6th Cir. 1997).
cites § 812.30 4×cited by 52 cases
Where it cites § 812.30
“” 21 C.F.R. § 812.30 . Once the device is approved under the IDE, the device is exempted from, among other things, compliance with performance standards and good manufacturing practice requirements.”
The case’s holding
State products liability claims are preempted when specific federal regulations apply to the device in question, such as those governing an investigational device exemption.
Later courts cite it for
“federal requirement 'must be applicable to the device in question... and specific to a particular device.” · 3 citing courts
2
GREENGoodlin v. Medtronic, Inc., 167 F.3d 1367 (11th Cir. 1999).
cites § 812.30 1×cited by 59 cases
Where it cites § 812.30
“See 21 C.F.R. § 812.30 (b)(4). 3 . For a detailed description of the PMA process, see Worthy v.”
The case’s holding
FDA premarket approval of a medical device does not impose an ascertainable federal requirement that preempts state law product liability claims.
Later courts cite it for
“neither the fda's actual review of a device and its supporting information nor the agency's eventual approval of the device imposes any ascertainable requirement upon the device.” · 4 citing courts
3
GREENBlinn v. Smith & Nephew Richards, Inc., 55 F. Supp. 2d 1353 (M.D. Fla. 1999).
cites § 812.30 1×cited by 18 cases
Where it cites § 812.30
“21 C.F.R. § 812.30 . IDEs are specifically exempted from many of the requirements to which they would otherwise be subject as Class III medical devices.”
Later courts cite it for
“under florida law.. .plaintiff cannot use a negligence per se claim to create a private cause of action for defendant's alleged violations of the fdca.” · 2 citing courts
4
GREENIsbell v. Medtronic, Inc., 97 F. Supp. 2d 849 (W.D. Tenn. 1998).
cites § 812.30 4×cited by 1 case
Where it cites § 812.30
“Based on the information submitted, the FDA will approve the device under the IDE unless “the risks to the subjects are not outweighed by the anticipated benefits to the subjects and the importance of the knowledge to be gained, or informed consent is inadequate, or the *853…”
5
GREENNexell Therapeutics, Inc. v. Amcell Corp., 143 F. Supp. 2d 407 (D. Del. 2001).
cites § 812.30 1×cited by 2 cases
Where it cites § 812.30
“IDE studies that are not scientifically sound in the context of device development, and will thus result in prolonging the investigation of your device, will be disapproved under 21 C.F.R. § 812.30 (b). Therefore, we request that you refrain from supplying your device to…”
6
GREENYale-New Haven Hosp. v. Leavitt, 470 F.3d 71 (2d Cir. 2006).
cites § 812.30 1×subsections: (b)(4)cited by 3 cases
Where it cites § 812.30
“3(m), if it determines that “[t]here is reason to believe that the risks to the subjects are not outweighed by the anticipated benefits to the subjects and the *85 importance of the knowledge to be gained,” 21 C.F.R. 812.30(b)(4). Use of significant risk devices in clinical…”
Later courts cite it for
“generally speaking, after-the-fact rationalization for agency action is disfavored.” · 4 citing courts
7
NO FLAGRobinson v. Endovascular Tech., Inc., 190 Cal. App. 4th 1490 (Ct. App. 2010).
cites § 812.30 3×cited by 0 cases
Where it cites § 812.30
“( 21 C.F.R. § 812.30 (1994).) *1494 After the IDE application has been approved, the FDA prohibits any deviation from the investigational plan, design, manufacturing techniques, clinical protocol, warnings or consent form which could potentially affect clinical subjects unless…”
8
GREENYale-New Haven Hosp. v. Leavitt, 470 F.3d 71 (2d Cir. 2006).
cites § 812.30 1×subsections: (b)(4)cited by 0 cases
Where it cites § 812.30
“3(m), if it determines that "[t]here is reason to believe that the risks to the subjects are not outweighed by the anticipated benefits to the subjects and the importance of the knowledge to be gained," 21 C.F.R. 812.30(b)(4). Use of significant risk devices in clinical trials…”
The case’s holding
An agency action is arbitrary and capricious if the agency fails to provide a reasoned explanation for a change in policy, as after-the-fact rationalization is generally disfavored.
9
GREENMize v. Mentor Worldwide LLC, 51 Cal. App. 5th 850 (Ct. App. 2020).
cites § 812.30 1×cited by 0 cases
Where it cites § 812.30
“( 21 C.F.R. § 812.30 .) If the FDA approves an IDE application, few changes to the investigational plan are permitted.”
10
GREENGoodlin v. Medtronic, Inc., 167 F.3d 1367 (11th Cir. 1999).
cites § 812.30 1×cited by 0 cases
Where it cites § 812.30
“See 21 C.F.R. § 812.30 (b)(4). 3 For a detailed description of the PMA process, see Worthy v.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199720082020

One bar per year. Tallest: 3 cases in 1999. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
11th Cir.22d Cir.2Cal. Ct. App.26th Cir.1D. Del.1M.D. Fla.1W.D. Tenn.1
By subsection
(b)(4)2 cases
Yale-New Haven Hosp. v. Leavitt, 470 F.3d 71 (2d Cir. 2006).“3(m), if it determines that “[t]here is reason to believe that the risks to the subjects are not outweighed by the anticipated benefits to the subjects and the *85 importance of the knowledge to be gained,” 21 C.F.R. 812.30(b)(4). Use of significant risk devices in clinical…”
Yale-New Haven Hosp. v. Leavitt, 470 F.3d 71 (2d Cir. 2006).“3(m), if it determines that "[t]here is reason to believe that the risks to the subjects are not outweighed by the anticipated benefits to the subjects and the importance of the knowledge to be gained," 21 C.F.R. 812.30(b)(4). Use of significant risk devices in clinical trials…”
Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com